Cell and Gene Therapy Deals Analysis, 2021-2024

    Published: June 3, 2024 | Price: $6,300.00 – $12,600.00

    Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 is published in two installments, the first in Q2 2024 and the second in Q4 2024. Customers who purchase the report will receive both installments. Kalorama Information’s Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that...
    Cell and Gene Therapy Funding and Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2023

    Published: December 8, 2023 | Price: $5,000.00 – $10,000.00

    While the concepts of gene therapy and cell therapy have been investigated for decades, there were major challenges in the early years.  Through incremental progress, and the gradual introduction of enabling tools such as CRISPR and next-generation sequencing (NGS), cell and gene therapy has emerged into a highly active area.  There are now many approved therapies with proven track records. As the technologies have lowered the barriers to entry for the industry, over 1,500 therapy or tools companies have been...
    Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals

    Published: May 22, 2023 | Price: $5,000.00 – $10,000.00

    This report, Kalorama's Cell and Gene Deals and Market Analysis, tracks the dealmaking and market opportunity in cell and gene therapy.   The report includes specific details of 1000+ deals from 2022-2023.   A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. Kalorama's CGT deals amounted to a staggering $40 billion in 2022.  Understanding the deals that have been made, who is making them, and what the specific details are is critical to...
    Cell Therapy and Gene Therapy Markets, 2021-2031

    Published: February 18, 2022 | Price: $6,000.00 – $12,000.00

    Authoritative Information on Cell and Gene Therapy Markets Cell Therapy And Gene Therapy Markets, 2021-2031 from Kalorama Information presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market) Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions) (Cell Therapy, Gene Therapy, Total Market) Cell...
    Cell and Gene Therapy Deals: Financings, Partnering, M&A, Technology Transfers, IPOs, and Other Developments

    Published: February 16, 2022 | Price: $5,000.00 – $10,000.00

    Cell and Gene Therapy Funding Reached $70 Billion in 2021. How Can You Keep Up with the Activity in this Industry? A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently.  There are now many approved therapies with proven track records.  As the tools have lowered the barriers to entry for the industry, over a thousand companies have been created or become involved.  Fortunately, Kalorama Information has been tracking every significant development in...
    Autoimmune Immunoassay Brief

    Published: September 29, 2021 | Price: $3,000.00 – $6,000.00

    A considerable number of diagnostic tests are available or in development for the detection of autoimmune diseases. Because of this potentially large and growing market, vast opportunity exists for discovery and advancement in this arena. Competition within this market is expected to increase dramatically. However, in fledgling autoimmune IVD diagnostic testing markets, a golden opportunity exists to capitalize on new testing innovations without significant competition. In terms of test options, a substantial amount of overlap exists in the various autoimmune...